<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Microb Cell Fact</journal-id><journal-id journal-id-type="iso-abbrev">Microb Cell Fact</journal-id><journal-title-group><journal-title>Microbial Cell Factories</journal-title></journal-title-group><issn pub-type="epub">1475-2859</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8724604</article-id><article-id pub-id-type="publisher-id">1722</article-id><article-id pub-id-type="doi">10.1186/s12934-021-01722-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Biosynthesis of <italic>C</italic>-nucleoside antibiotics in actinobacteria: recent advances and future developments</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Meng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kong</surname><given-names>Liyuan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Gong</surname><given-names>Rong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Iorio</surname><given-names>Marianna</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Donadio</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Zixin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sosio</surname><given-names>Margherita</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2557-8960</contrib-id><name><surname>Chen</surname><given-names>Wenqing</given-names></name><address><email>wqchen@whu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.49470.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2331 6153</institution-id><institution>Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, and School of Pharmaceutical Sciences, </institution><institution>Wuhan University, </institution></institution-wrap>Wuhan, 430071 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.16821.3c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 8293</institution-id><institution>State Key Laboratory of Microbial Metabolism, and School of Life Sciences and Biotechnology, </institution><institution>Shanghai Jiao Tong University, </institution></institution-wrap>Shanghai, 200240 China </aff><aff id="Aff3"><label>3</label>Naicons Srl, Viale Ortles 22/4, 20139 Milan Italy </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>1</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>1</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>21</volume><elocation-id>2</elocation-id><history><date date-type="received"><day>4</day><month>11</month><year>2021</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Epidemic diseases and antibiotic resistance are urgent threats to global health, and human is confronted with an unprecedented dilemma to conquer them by expediting development of new natural product related drugs. <italic>C</italic>-nucleoside antibiotics, a remarkable group of microbial natural products with diverse biological activities, feature a heterocycle base linked with a ribosyl moiety via an unusual <italic>C</italic>-glycosidic bond, and have played significant roles in healthcare and for plant protection. Elucidating how nature biosynthesizes such a group of antibiotics has provided the basis for engineered biosynthesis as well as targeted genome mining of more <italic>C</italic>-nucleoside antibiotics towards improved properties. In this review, we mainly summarize the recent advances on the biosynthesis of <italic>C</italic>-nucleoside antibiotics, and we also tentatively discuss the future developments on rationally accessing <italic>C</italic>-nucleoside diversities in a more efficient and economical way via synthetic biology strategies.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Natural product</kwd><kwd><italic>C</italic>-nucleoside antibiotics</kwd><kwd>Biosynthesis</kwd><kwd>Genome mining</kwd><kwd>Synthetic biology</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31770041</award-id><award-id>31970052</award-id><award-id>32170026</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Wenqing</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par33">Nucleoside antibiotics play significant roles in mammalian healthcare and for plant protection against pathogen-induced infections [<xref ref-type="bibr" rid="CR1">1</xref>], and they are usually synthesized by sequential modifications of nucleosides or nucleotides of primary origin to render the intricate molecules [<xref ref-type="bibr" rid="CR2">2</xref>]. Nucleoside antibiotics, on the basis of the linkage by glycosidic bond, can be generally classified into two main categories, either <italic>N</italic>- or <italic>C</italic>-nucleosides. Normally, <italic>N</italic>-nucleosides are structurally unstable and susceptible to cleavage of the glycosidic bond with loss of bioactivity, which has raised considerable research interests in the past decades towards the development of <italic>C</italic>-nucleoside derived drugs [<xref ref-type="bibr" rid="CR3">3</xref>]. Actually, nature, as a great chemist, has developed the great capability of creating the <italic>C</italic>-nucleosides prior to the synthesis of artificial molecules, and pseudouridine (&#x003a8;) is the first naturally-occurring <italic>C</italic>-nucleoside found abundantly in tRNA [<xref ref-type="bibr" rid="CR4">4</xref>]. Since then, several <italic>C</italic>-nucleoside antibiotics have been successively isolated in the past decades.</p><p id="Par34">Although <italic>C</italic>-nucleoside antibiotics (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a&#x02013;c), including showdomycin (SDM), minimycin (MIN), formycin A (FOR-A), pyrazofurin A (PRF-A), malayamycin A (MAL-A), and pseudouridimycin (PUM), have been demonstrated to be an attractive group of natural products as leads in pharmaceutical development, their biosynthesis is poorly understood and has not been systematically investigated until recently. According to the enzymatic strategies employed for the construction of <italic>C</italic>-glycosidic bonds, the six <italic>C</italic>-nucleoside antibiotics can be divided into three sub-groups (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a&#x02013;c). For the SDM and MIN molecules, C&#x02013;C bond construction is dependent on a YeiN-like (YeiN, pseudouridine-5&#x02032;-phosphate glycosidase from <italic>Escherichia coli</italic>)&#x000a0;<italic>C</italic>-glycosynthase (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], while FOR-A and PRF-A biosynthesis utilize a &#x003b2;-ribofuranosyl-aminobenzene 5&#x02032;-phosphate (&#x003b2;-RFAP) synthase-like enzyme to catalyze the <italic>C</italic>-glycoside bond formation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. As for the MAL-A and PUM nucleoside antibiotics, a tRNA pseudouridylate synthase (TruD-like) has been identified to be involved in the <italic>N</italic>- to <italic>C</italic>-isomerization of a nucleoside-like intermediate (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Chemical structures of <italic>C-</italic>nucleoside antibiotics featured in this review. <bold>a</bold> Structures of showdomycin (SDM), minimycin (MIN) and related compounds; this subgroup employs a YeiN-like strategy for <italic>C</italic>-glycosidic bond construction. <bold>b</bold> Structures of formycin A (FOR-A), pyrazofurin A (PRF-A) and structural analogs; for this subgroup, &#x003b2;-RFAP (&#x003b2;-ribofuranosyl-aminobenzene 5&#x02032;-phosphate) synthase-like enzymes govern <italic>C</italic>-nucleoside scaffold construction in the biosynthesis of FOR-A and PRF-A. <bold>c</bold> Structures of tRNA, malayamycin A (MAL-A), and pseudouridimycin (PUM); the tRNA pseudouridylate synthases (TruD-like) are responsible for <italic>C</italic>-glycosidic bond formation in MAL-A and PUM biosynthesis</p></caption><graphic xlink:href="12934_2021_1722_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Mechanism of C&#x02013;C bond formation for related antibiotics. <bold>a</bold> The YeiC phosphorylates pseudouridine to produce PsiMP, and then hydrolyzed to uracil and ribose 5-P by YeiN. <bold>b</bold> &#x003b2;-RFAPS catalyzes the condensation of <italic>p</italic>-aminobenzoate (<italic>p</italic>ABA) and PRPP to &#x003b2;-RFAP. <bold>c</bold> The pseudouridine is generated from isomerization of uridine-tRNA, catalyzed by TruD. YeiC, pseudouridine kinase; ribose 5-P, ribose-5&#x02032;-Phosphate; &#x003b2;-RFAPS, &#x003b2;-RFAP synthase</p></caption><graphic xlink:href="12934_2021_1722_Fig2_HTML" id="MO2"/></fig></p><p id="Par35">Several biosynthetic gene clusters (BGCs) of actinobacterial <italic>C</italic>-nucleosides have been recently identified and characterized [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], which, for the first time, has enabled scientists to explore the biosynthetic panorama of them, and has also provided the basis for future <italic>C</italic>-nucleoside-derived drug discovery and development. More than that, the reservoirs of the conserved genes for <italic>C</italic>-nucleosides biosynthesis have been increased with unprecedented speed in the past few years, accordingly, genome mining, as an integrated and powerful strategy, has been conferred with great capacities to revitalize the process for the rapid and rational discovery of more novel <italic>C</italic>-nucleoside molecules with diverse biological activities [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par36">In this review, we mainly summarize the recent progress on the biosynthesis of <italic>C</italic>-nucleoside antibiotics. Moreover, we tentatively delineate the perspectives as well on the rapid discovery and rational generation of more <italic>C</italic>-nucleoside antibiotics with utilization of synthetic biology strategies.</p></sec><sec id="Sec2"><title>Biosynthesis of the YeiN-like type <italic>C</italic>-nucleoside antibiotics</title><sec id="Sec3"><title>Biosynthesis of showdomycin features disassociated NRPS enzymes</title><p id="Par37">Showdomycin (SDM) was isolated from <italic>Streptomyces showdoensis</italic> ATCC 15227 (<italic>S. showdoensis</italic>, likewise, other strains were abbreviated in this paper) in 1964 and was synthesized chemically in 1970 [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. The structure of SDM is shown as 3-&#x003b2;-<sc>d</sc>-ribofuranosylmaleimide, which possesses a unique maleimide-type ring. The SDM molecule is structurally related to pseudouridine but lacks a &#x02013;NH group in heterocycle [<xref ref-type="bibr" rid="CR16">16</xref>]. SDM shows a broad spectrum activity against Gram-positive and Gram-negative bacteria, moreover, it is active against HeLa cells and Ehrlich mouse ascites tumor in vivo by inhibiting DNA and RNA polymerases [<xref ref-type="bibr" rid="CR16">16</xref>]. Previous feeding studies demonstrated that succinate, fumarate, malate, and acetate are converted to &#x003b1;-ketoglutarate or glutamate via the Krebs cycle in <italic>S. showdoensis,</italic> and &#x003b1;-ketoglutarate is then decarboxylated to give rise to an asymmetrical C4&#x000a0;unit which serves as C-2 to C-5 of maleimide ring as for the ribosyl moiety, it is directly originated from <sc>d</sc>-ribose [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par38">The SDM BGC was identified from the genome of <italic>S. showdoensis</italic> using AlnA (<italic>C</italic>-glycosynthase) and AlnB (phosphatase) from alnumycin pathway as the query sequences, and the SDM BGC is composed of 16 genes and spans a 12.2-kb continuous chromosome region (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR5">5</xref>]. Biosynthesis of the SDM molecule is proposed to be initiated by the cyclase SdmE, which is responsible for the cyclization of the substrate <sc>l</sc>-glutamine. Then the intermediate <bold>1</bold> (2-amino-1-pyrroline-5-carboxylate) is activated by the nonribosomal peptide synthetases SdmC to produce compound <bold>2</bold>, which is subsequently loaded onto the phosphopantetheine arm of the peptidyl carrier protein SdmD. The tethered intermediate subsequently undergoes successive oxidation and hydrolysis to synthesize <bold>4</bold> [<xref ref-type="bibr" rid="CR20">20</xref>], afterwards, this intermediate (<bold>4</bold>) is sequentially catalyzed by <italic>C</italic>-glycosynthase SdmA and dephosphatase SdmB to produce the intermediate <bold>6</bold>, which experiences a series of nonenzymatic steps including decarboxylation, deamination, and oxidoreduction to generate the end product SDM (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b) [<xref ref-type="bibr" rid="CR20">20</xref>]. Actually, the proposed SDM biosynthetic pathway has been as yet incompletely understood.<fig id="Fig3"><label>Fig. 3</label><caption><p>Genetic organization of the SDM gene cluster and its proposed biosynthetic pathway. <bold>a</bold> Genetic organization of the SDM gene cluster. The gene cluster (<italic>sdm</italic>) was identified from <italic>S. showdoensis</italic> ATCC 15227. <bold>b</bold> Proposed biosynthetic pathway to SDM. The gene organization was analyzed by BLAST (<ext-link ext-link-type="uri" xlink:href="https://blast.ncbi.nlm.nih.gov/Blast.cgi">https://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link>), antiSMASH (<ext-link ext-link-type="uri" xlink:href="https://antismash.secondarymetabolites.org/#!/start">https://antismash.secondarymetabolites.org/#!/start</ext-link>), and 2ndfind (<ext-link ext-link-type="uri" xlink:href="https://biosyn.nih.go.jp/2ndfind/">https://biosyn.nih.go.jp/2ndfind/</ext-link>), and these online programs were used as well for the bioinformatics analysis of other gene clusters and genomes mentioned in this paper</p></caption><graphic xlink:href="12934_2021_1722_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of the bioactivities and biological targets for the described natural nucleoside antibiotics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Antibiotics</th><th align="left">Producing strains</th><th align="left">Bioactivities</th><th align="left">Biological targets</th><th align="left">BGC Accession no</th></tr></thead><tbody><tr><td align="left">Showdomycin</td><td align="left"><italic>S. showdoensis</italic> ATCC 15227</td><td align="left">Antibacterial</td><td align="left">DNA and RNA polymerases</td><td align="left">LAQS00000000<sup>a</sup></td></tr><tr><td align="left">Minimycin</td><td align="left"><italic>S. hygroscopicus</italic> JCM 4712</td><td align="left">Antibacterial, antitumor</td><td align="left">RNA polymerase</td><td align="left">MK122964</td></tr><tr><td align="left">Formycin A</td><td align="left"><p><italic>Noc. interforma</italic> ATCC 21072</p><p><italic>S. kaniharaensis</italic> ATCC 21070</p></td><td align="left">Antiviral, antibacterial</td><td align="left">Adenosine kinase</td><td align="left"><p>KY682079</p><p>KY705052</p><p>MK830994</p><p>WBOF00000000<sup>b</sup></p></td></tr><tr><td align="left">Pyrazofurin A</td><td align="left"><italic>S. candidus</italic> NRRL 3601</td><td align="left">Antiviral, antitumor</td><td align="left">OMP decarboxylase</td><td align="left"><p>MH493900</p><p>MN305320</p></td></tr><tr><td align="left">Malayamycin A</td><td align="left"><p><italic>S. malaysiensis</italic> DSM 14072</p><p><italic>S. chromofuscus</italic> ATCC 49982</p></td><td align="left">Antiviral, antifungal, anticancer</td><td align="left">Unknown</td><td align="left"><p>KJ493330</p><p>MH537786</p></td></tr><tr><td align="left">Pseudouridimycin</td><td align="left"><p><italic>Streptomyces</italic> sp. ID38640</p><p><italic>S. albus</italic> DSM 40763</p></td><td align="left">Antibacterial</td><td align="left">RNA polymerase</td><td align="left"><p>MG266907</p><p>RCIY01000000<sup>c</sup></p></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The SDM BGC occupies an approximate 12.2-kb chromosomal region in <italic>S. showdoensis</italic> ATCC 15227</p><p><sup>b</sup>The genome sequence of <italic>S. kaniharaensis</italic> ATCC 21070 is available in GenBank with the accession number WBOF00000000</p><p><sup>c</sup>The PUM BGC from <italic>S. albus</italic> DSM 40763 is available with the accession RCIY00000000</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Biosynthesis of minimycin highlights a NRPS machinery</title><p id="Par39">Minimycin (MIN) (also called oxazinomycin) was produced by both <italic>Streptomyces</italic> sp. and <italic>Pseudomonas</italic> sp. [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. The MIN molecule distinguishes a unique structural system, in which the 1,3-oxazine-2,4-dione ring and the ribosyl sugar are linked via a C&#x02013;C bond [<xref ref-type="bibr" rid="CR24">24</xref>]. MIN is structurally similar to pseudouridine, and actually it is prone to being slightly converted to pseudouridine under mild alkaline environment [<xref ref-type="bibr" rid="CR25">25</xref>]. MIN is active against both Gram-positive and Gram-negative bacteria; moreover, it possesses antitumor activity against transplantable tumors [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Recently, MIN is revealed to be able to inhibit RNA polymerase at the polythymidine sequences, whereas the detailed action mechanism of MIN has as yet been unclear [<xref ref-type="bibr" rid="CR26">26</xref>]. With regards to the biosynthetic origin of MIN, C-6, C-5, and C-4 of the oxazine ring arise from the corresponding C-3, C-4, and C-5 of <sc>l</sc>-glutamate, and the C-2 of MIN is derived from carbon dioxide, and the ribosyl portion of MIN derives from ribose [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par40">The MIN biosynthetic gene cluster has recently been identified and characterized, and the intact MIN BGC consists of five essential genes involving <italic>minA</italic>, <italic>minB</italic>, <italic>minC</italic>, <italic>minD</italic>, and <italic>minT</italic> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>]. MinA (non-ribosomal peptide synthetase, NRPS), MinB (<italic>C</italic>-glycosynthase), and MinC (HAD phosphatase and DUF4243 domain) are confirmed to be responsible for synthesizing the MIN compound [<xref ref-type="bibr" rid="CR6">6</xref>]. Biosynthesis of the MIN molecule is started by the NRPS enzyme MinA, and the substrate <sc>l</sc>-glutamine can be specifically selected and activated by adenylation domain (A domain) in the presence of ATP, and then the activated amino acid is tethered on the thiolation domain (T domain). The C<sub>&#x003b1;</sub>-H of the tethered <sc>l</sc>-glutamine is deprotonated by the conserved active site (Tyr residue) in oxidase domain which initiates the oxidation reaction at C-2 to C-3 positions [<xref ref-type="bibr" rid="CR29">29</xref>]. The oxidized complex is successively cyclized and released by the thioesterase domain (TE domain) to obtain the intermediate compound <bold>7</bold>, which can be converted to indigoidine by a spontaneous coupling reaction. Simultaneously, this intermediate can also be tautomerized by the tautomerase domain (Tau domain) to generate compound <bold>8</bold>, which is accepted by MinB as substrate for <italic>C-</italic>glyosidic bond construction to form compound <bold>9</bold> [<xref ref-type="bibr" rid="CR6">6</xref>]. Finally, the intermediate <bold>9</bold> is sequentially catalyzed by the <italic>C</italic>-terminal domain and <italic>N</italic>-terminal domain of MinC (MinC<sub>C</sub> and MinC<sub>N</sub>, respectively) to synthesize the end molecule MIN, with undergoing an unusual oxidative deamination&#x02013;recombination reaction associated with the final dephosphorylation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) [<xref ref-type="bibr" rid="CR6">6</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>The gene cluster as well as the proposed pathway for MIN biosynthesis. <bold>a</bold> Genetic organization of the MIN gene clusters; the gene cluster was cloned from <italic>S. hygroscopicus</italic> JCM 4712. <bold>b</bold> Proposed biosynthetic pathways to MIN; A, adenylation domain; Ox, oxidase domain; T, thiolation domain; TE, thioester domain; Tau, tautomerase domain</p></caption><graphic xlink:href="12934_2021_1722_Fig4_HTML" id="MO4"/></fig></p><p id="Par41">More interestingly, MIN biosynthesis employs an unprecedented self-resistance mechanism. In this resistance system, most of the intracellular compound <bold>10</bold> (MIN monophosphate) was dephosphorylated by MinC<sub>N</sub> (the <italic>N</italic>-terminal phosphatase domain of MinC) to produce MIN, and most of MIN was transported out of the cell by the transporter MinT, thereby greatly alleviating the toxic effect of intracellular MIN monophosphate. Moreover, MinD (uracil phosphoribosyltransferase) enhances the concentration of in vivo UMP pool to achieve the competition advantage against the relatively poor amount of cellular MIN monophosphate. Accordingly, MinC<sub>N</sub>, MinD, and MinT function together as safeguard enzymes, and collaborate to fulfill the mission of self-resistance during MIN biosynthesis [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec></sec><sec id="Sec5"><title>Biosynthesis of the &#x003b2;-RFAP synthase-like type <italic>C</italic>-nucleoside molecules</title><sec id="Sec6"><title>Formycin A biosynthesis features an unusual pathway for pyrazole ring formation</title><p id="Par42">Formycin A (FOR-A) was first isolated from the fermentation broth of <italic>Nocardia interforma</italic> in 1964 during the searching for antitumor compounds [<xref ref-type="bibr" rid="CR30">30</xref>]. This antibiotic has also been discovered in culture filtrates of other strains, including <italic>Streptomyces lavendulae</italic> [<xref ref-type="bibr" rid="CR31">31</xref>], <italic>Streptomyces kaniharaensis</italic> ATCC 21070 (<italic>S. kaniharensis</italic>) [<xref ref-type="bibr" rid="CR32">32</xref>], and <italic>Streptomyces resistomycificus</italic> NRRL 2290 [<xref ref-type="bibr" rid="CR7">7</xref>]. Subsequently, FOR-A and coformycin (COF) (an adenosine deaminase inhibitor harboring a 1,3-diazepine ring) were found to be concomitantly produced by these strains [<xref ref-type="bibr" rid="CR7">7</xref>]. The structure of FOR-A was illustrated and confirmed as 7-amino-3-&#x003b2;-<sc>d</sc>-ribofuranosyl-1H-pyrazolo-[4,3d] pyrimidine by X-ray crystallography [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. FOR-A, as an adenosine analog targeting adenosine kinase, exhibits significant antitumor activity against <italic>Ehrlich carcinoma</italic> in mice as well as HeLa cells [<xref ref-type="bibr" rid="CR30">30</xref>], moreover, it exhibits antiviral activity against influenza virus A1 and human immunodeficiency virus type 1 [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. However, FOR-A has to be phosphorylated at the 5&#x02032; position to give the active molecule FOR-A monophosphate, which is able to block the de novo biosynthesis of purine and pyrimidine nucleotides [<xref ref-type="bibr" rid="CR38">38</xref>]. Structurally, ribosyl moiety of FOR-A is derived from ribose of phosphoribosyl pyrophosphate (PRPP) [<xref ref-type="bibr" rid="CR39">39</xref>], and the N-3 and N-8 atoms of FOR-A originate from the &#x003b5;-amino group of <sc>l</sc>-lysine (<sc>l</sc>-Lys) [<xref ref-type="bibr" rid="CR40">40</xref>]. Moreover, the C-6, C-5, C-4, and C-9 carbons of FOR-A are derived from the C-1, C-2, C-3, and C-4 carbons of glutamate [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par43">Recent investigations have illuminated that the pyrazolopyrimidine moiety of FOR-A was formed in a similar manner to that of adenosine [<xref ref-type="bibr" rid="CR42">42</xref>], which is actually assembled by the Pur enzymes, including adenylosuccinate synthetase PurA, adenylosuccinate lyase PurB<italic>,</italic> SAICAR (phosphoribosylaminoimidazole-succinocarboxamide) synthetase PurC, and AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) transformylase PurH. In a recent study, two sets of Pur enzymes were identified in genome of <italic>S. kaniharaensis</italic>, and the second set of Pur-like enzymes (the counterpart for enzymes) is undoubtedly involved in the biosynthesis of FOR-A [<xref ref-type="bibr" rid="CR43">43</xref>]. A draft genome sequence of <italic>S. kaniharaensis</italic> was assembled from 19 polished contigs with an N50 contig length of 6,153,183&#x000a0;bp [<xref ref-type="bibr" rid="CR44">44</xref>]. The gene cluster from <italic>S. kaniharaensis</italic> is composed of 30 genes, and occupies a ca. 37.0-kb continuous chromosomal region, while the counterpart <italic>foc</italic> gene cluster (26 genes) from <italic>Nocardia interforma</italic> ATCC 21072 is ca. 29.4-kb in size (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a, Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>]. More interestingly, the antibiotic pair COF-FOR-A also employs an unusual but general protector-prot&#x000e9;g&#x000e9; strategy; i.e., COF may protect FOR-A from deamination by the housekeeping adenosine deaminase [<xref ref-type="bibr" rid="CR45">45</xref>].<fig id="Fig5"><label>Fig. 5</label><caption><p>The gene clusters and corresponding pathways for FOR-A and PRF-A biosynthesis. <bold>a</bold> Genetic organization of the PRF-A and FOR-A gene clusters. The PRF-A gene cluster (<italic>prf</italic>) was from <italic>S. candidus</italic> NRRL 3601, and the FOR-A and COF gene cluster was from <italic>Nocardia interforma</italic> ATCC 21072 and from <italic>S. kaniharaensis</italic> ATCC 21070, respectively. <bold>b</bold> Proposed pathways to FOR-A and PRF-A. They share identical steps at the early stage prior to the construction of <italic>C</italic>-nucleoside scaffolds. HDCP, 4-hydroxy-3,5-dicarboxypyrazole; DCOP, 3,5-dicarboxy-4-oxo-4,5-dihydropyrazole; ADCP, 4-amino-3,5-dicarboxypyrazole</p></caption><graphic xlink:href="12934_2021_1722_Fig5_HTML" id="MO5"/></fig></p><p id="Par44">Biosynthesis of FOR-A is initiated by ForK (<sc>l</sc>-Lys <italic>N</italic><sup><italic>6</italic></sup>-monooxygenase) with hydroxylation of <sc>l</sc>-Lys to form <italic>N</italic><sup><italic>6</italic></sup>-OH <sc>l</sc>-Lys [<xref ref-type="bibr" rid="CR7">7</xref>]. Subsequently, <italic>N</italic><sup><italic>6</italic></sup>-OH <sc>l</sc>-Lys and <sc>l</sc>-glutamate are catalyzed by methionine-tRNA ligase ForJ, with constructing the unusual N&#x02013;N bond of compound <bold>11</bold> between the &#x003b1;-amino group of Glu and the &#x003b5;-amino group of Lys. Then, the amino acid oxidase PrfR, catalyzes the oxidative cleavage of the C&#x02013;N bond of <bold>11</bold> to form compound <bold>12</bold> [<xref ref-type="bibr" rid="CR46">46</xref>], which then experiences sequential reactions to build 3,5-dicarboxy-4-oxo-4,5-dihydropyrazole (DCOP). After successive reactions by ForI (aminotransferase) and ForF (phosphoglycerate dehydrogenase), DCOP is catalyzed to form ADCP (4-amino-3,5-dicarboxypyrazole). ForT (&#x003b2;-ribofuranosyl-aminobenzene 5&#x02032;-phosphate synthase-like enzymes) is responsible for the condensation of PRPP and ADCP to form a carboxyaminopyrazole ribonucleotide via a similar mechanism employed in methanopterin biosynthesis [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. After that, <bold>13</bold> is converted to <bold>19</bold> through sequential enzymatic steps closely identical to those in the purine biosynthetic pathway of primary metabolism [<xref ref-type="bibr" rid="CR42">42</xref>]. After final dephosphorylation, compound <bold>19</bold> is catalyzed to form the end product FOR-A (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). The crystal structures and mechanisms of several enzymes, involving the PLP-dependent transaminase ForI [<xref ref-type="bibr" rid="CR47">47</xref>] and the <italic>C</italic>-glycoside synthase ForT [<xref ref-type="bibr" rid="CR48">48</xref>], have recently been solved and elucidated, which will provide the solid basis for the further engineering of FOR biosynthesis towards improved production/activities.</p></sec><sec id="Sec7"><title>The biosynthetic pathways of pyrazofurin A and formycin A are overlapped</title><p id="Par45">Pyrazofurin (PRF-A) was isolated from the cultures of <italic>Streptomyces candidus</italic> NRRL 3601 (<italic>S. candidus</italic>) in 1969, and its structure is 4-hydroxy-3-&#x003b2;-<sc>d</sc>-ribofuranosyl-pyrazole-5-carboxamide as determined by a combination of spectroscopy and chemical degradation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR49">49</xref>]. Both PRF-A and FOR-A feature pyrazole-derived nucleobases, either imidazolopyrimidine (for PRF-A) or pyrazolopyrimidine (for FOR-A), which are obviously different from the typical nucleosides [<xref ref-type="bibr" rid="CR50">50</xref>]. Recently, PRF-A and formycin B (a deaminated product of FOR-A) were synthesized with seven steps by employing a sydnone riboside as common intermediate [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par46">In the past decades, PRF-A has been of great research interests in medicinal chemistry due to its remarkable activities and application potential [<xref ref-type="bibr" rid="CR52">52</xref>]. PRF-A harbors notable antiviral and antitumor activities, moreover, this molecule indicates antineoplastic activity in rats and is also active to a relatively broad range of tumors, including Walker carcinosarcoma, plasma cell myeloma, and various types of lymphosarcoma and breast carcinoma [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Mechanistically, PRF-A targets orotidine-5&#x02032;-monophosphate (OMP) decarboxylase with rendering inhibition of pyrimidine biosynthesis, simultaneously, this <italic>C</italic>-nucleoside molecule is also a potent inhibitor of 5-aminoimidazole-4-carboxamide ribotide (AICAR) transformylase of the purine pathway [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Initially, PRF-A has been tentatively developed as a potential anticancer drug, unfortunately, unsatisfactory results were emerged in the phase I clinical trials because of its toxicity to human cells [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Afterwards, development of PRF-A as a potential antitumor drug has gradually faded. However, a recent study with exciting result that PRF-A was demonstrated to be effective against SARS-associated coronaviruses, making it potential to develop antiviral interventions of the global pandemic COVID-19 [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par47">Concerning the biosynthetic origin of PRF-A, C-3 to C-6 unit of PRF-A is derived from C-4 to C-1 of glutamate and/or &#x003b1;-ketoglutarate on the basis of previous isotope feeding experiments [<xref ref-type="bibr" rid="CR60">60</xref>], and the gene cluster of PRF-A was recently identified from <italic>S. candidus</italic> using FocJ (an annotated methionine-tRNA ligase) as the query sequence [<xref ref-type="bibr" rid="CR7">7</xref>]. The <italic>prf</italic> gene cluster consists of 24 genes and occupies a continuous 27.1-kb chromosomal region (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a, Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR7">7</xref>]. More surprisingly, the genes for COF biosynthesis were also revealed to be existed in <italic>prf</italic> gene cluster, however, no related product was identified from cultures in recent studies [<xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par48">The PRF-A molecule is structurally similar to FOR-A, and the pathways of them are actually overlapped. The biosynthetic pathway of PRF-A, resembling that of FOR-A, also contains a pyrazole-related intermediate DCOP, which spontaneously undergoes keto-enol isomerization to form 4-hydroxy-3,5-dicarboxypyrazole (HDCP). After that, HDCP and PRPP are catalyzed by PrfT (&#x003b2;-ribofuranosyl-aminobenzene 5&#x02032;-phosphate synthase-like enzymes) to form C&#x02013;C bond of compound <bold>20</bold> [<xref ref-type="bibr" rid="CR7">7</xref>]<bold>.</bold> Finally, PrfC (SAICAR synthetase) and PrfB (a putative adenylsuccinate lyase) are shown to catalyze amidation of compound <bold>20</bold> to generate pyrazofurin 5&#x02032;-phosphate (compound <bold>21</bold>). Subsequently, this intermediate is under catalysis of PrfB with leaving of a fumarate. After removal of phosphate group, biosynthesis of the end molecule PRF-A is accomplished (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b) [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec></sec><sec id="Sec8"><title>Biosynthesis of the TruD-like type <italic>C</italic>-nucleoside natural products</title><sec id="Sec9"><title>Biosynthesis of malayamycin A resembles polyoxin in the backbone construction</title><p id="Par49">Malayamycin A (MAL-A), was originally isolated from broth of the soil bacterium <italic>Streptomyces malaysiensis</italic> DSM&#x000a0;14702 (<italic>S. malaysiensis</italic>) by a group at the Syngenta Crop Protection laboratories in Jealott&#x02019;s Hill, U.K [<xref ref-type="bibr" rid="CR62">62</xref>], and the MAL-A molecule contains a bicyclic perhydrofuropyran &#x0201c;sugar&#x0201d; moiety rather than the more commonly encountered monocyclic pentofuranosyl or hexopyranosyl core [<xref ref-type="bibr" rid="CR63">63</xref>]. MAL exhibits potent antiviral, antifungal, and anticancer bioactivity, moreover, MAL displays broad spectrum activity against phytopathogenic fungi in the greenhouse, for instance, MAL inhibits sporulation of <italic>Stagonospora nodorum</italic> (Berk) Castell &#x00026; Germano, the cause of <italic>Stagonospora nodorum</italic> blotch of wheat [<xref ref-type="bibr" rid="CR64">64</xref>], while the detailed action mechanism for MAL has still remained obscure.</p><p id="Par50">The discovery and characterization of the biosynthetic pathway to MAL-A was previously reported using genome mining of near-identical clusters both from the known producer <italic>S. malaysiensis</italic> and from <italic>S. chromofuscus</italic> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a, Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR10">10</xref>]. A strong candidate to be the MAL-A biosynthetic gene cluster, comprises 20 predicted open reading frames. The biosynthesis of MAL-A may utilize uridine as a starter substrate by pseudouridine synthase TruD to generate pseudouridine [<xref ref-type="bibr" rid="CR10">10</xref>], which is susceptible to be phosphorylated to produce 5&#x02032;-pseudouridine monophosphate (5&#x02032;-&#x003a8;-MP). After that, 5&#x02032;-&#x003a8;-MP was catalyzed by MalO (enoylpyruvyl transferase) acting almost exclusively on 5&#x02032;-&#x003a8;-MP to yield compound <bold>23</bold>. Then, the radical SAM enzyme MalJ is proposed to catalyze C&#x02013;C bond formation utilizing a previously-characterized strategy in nikkomycin/polyoxin biosynthesis to form compound <bold>24</bold>, which is then catalyzed by enzymes containing phosphatase MalL, 2-oxoglutarate-Fe (II)-dependent oxygenases MalM and MalI, and aminotransferase MalK to build compound <bold>26</bold> [<xref ref-type="bibr" rid="CR10">10</xref>]. After the final tailoring enzymatic steps by the carbamoyltransferase MalD and the <italic>O</italic>-methyltransferase MalF, biosynthesis of the end <italic>C</italic>-nucleoside molecule MAL-A is accomplished (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b) [<xref ref-type="bibr" rid="CR10">10</xref>].<fig id="Fig6"><label>Fig. 6</label><caption><p>The gene clusters and proposed pathway for MAL-A biosynthesis. <bold>a</bold> Organization of the MAL-A gene clusters (<italic>mal</italic>), which is independently identified from <italic>S. chromofuscus</italic> ATCC 49982 and <italic>S. malaysiensis</italic> DSM 14072. <bold>b</bold> The proposed biosynthetic pathway to MAL-A</p></caption><graphic xlink:href="12934_2021_1722_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec10"><title>Biosynthesis of the bacterial RNA polymerase-pseudouridimycin</title><p id="Par51">In 2017, it has been reported the identification and complete characterization of pseudouridimycin (PUM), a new <italic>C</italic>-nucleoside antibiotic from <italic>Streptomyces</italic> sp. ID38640, by a team of scientists from Rutgers University and from Naicons in collaboration with the university of Milan and the university of Bonn [<xref ref-type="bibr" rid="CR65">65</xref>]. PUM is a peptidyl nucleoside, and is composed of a cored 6&#x02032;-amino-pseudouridine and a formamidinylated, <italic>N</italic>-hydroxylated glycine&#x02013;glutamine side chain [<xref ref-type="bibr" rid="CR66">66</xref>]. PUM covers a broad antibacterial spectrum, including some drug-sensitive and drug-resistant strains, which is due to its high affinity and unusual mechanism with its target, RNA polymerase (RNAP) [<xref ref-type="bibr" rid="CR67">67</xref>]. PUM can mimic the substrate of RNAP, nucleoside-triphosphate (NTP), then accurately occupies and tightly binds the NTP addition site on RNAP by preventing the addition of NTP [<xref ref-type="bibr" rid="CR68">68</xref>]. Another exciting feature of PUM is its selectivity: it can selectively inhibit the bacterial RNAP polymerase (bRNAP) in vitro rather than human RNA polymerase (hRNAP) [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par52">The PUM biosynthetic gene cluster has been identified in <italic>Streptomyces</italic> sp. ID38640, and the <italic>pum</italic> cluster is likely to encompass a genomic segment of about 20-kb consisting of 15 genes (designated <italic>puma</italic>&#x02013;<italic>pumO</italic>) associated with PUM biosynthesis, export, and regulation (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR9">9</xref>]. The knock-out mutant strains were correspondingly able to accumulate the specialized intermediates, including pseudouridine (PU), 5&#x02032;-amino pseudouridine (APU), Gln-APU, <italic>N</italic>-hydroxy-Gln-APU guanidinoacetic acid (GAA) [<xref ref-type="bibr" rid="CR9">9</xref>]. Recently, the minimal PUM BGC was generated and expressed in the heterologous host <italic>Streptomyces coelicolor</italic> M1146 under control of strong promotors including <italic>pumB</italic> and <italic>pumD&#x02013;N</italic> [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Besides that, all core genes involved in the formation PUM could be identified in <italic>Streptomyces albus</italic> DSM 40763 (<italic>S. albus</italic>), a previously reported strain capable of producing the <italic>C</italic>-nucleoside strepturidin, which leads to the structural revision of the antibiotic as PUM. Actually, the core <italic>sap</italic> (the gene cluster of PUM from <italic>S. albus</italic>) and <italic>pum</italic> gene clusters share both significant homology and the almost-identical genetic organization (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a) [<xref ref-type="bibr" rid="CR73">73</xref>]. Based on in silico analysis, genetic, and feeding experiments of precursors or intermediates, the complete PUM biosynthetic pathway was tentatively proposed as indicated in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>b [<xref ref-type="bibr" rid="CR71">71</xref>].<fig id="Fig7"><label>Fig. 7</label><caption><p>Genetic organization of the PUM gene cluster and the proposed pathway to PUM. <bold>a</bold> Genetic organization of the PUM gene cluster. The gene cluster (<italic>pum</italic>) was from <italic>Streptomyces</italic> sp. ID38640. The <italic>sap</italic> gene cluster was from <italic>Streptomyces albus</italic> DSM 40763, show high homology to <italic>pum</italic> gene cluster. <bold>b</bold> Proposed biosynthetic pathways to PUM. APU, 5&#x02032;-amino pseudouridine; Glu-APU, Glutamine-APU; GAA, guanidino acetic acid. X&#x02009;=&#x02009;H or PO<sub>3</sub>H<sub>2</sub></p></caption><graphic xlink:href="12934_2021_1722_Fig7_HTML" id="MO7"/></fig></p><p id="Par53">In the proposed pathway to PUM, the initial substrate uridine is isomerized to <italic>C</italic>-nucleoside intermediate <bold>28</bold> by the tRNA pseudouridine synthase PumJ (TruD-like pseudouridylate synthase), and the cored nucleoside region is successively modified by oxidoreductase PumI and aminotransferase PumG to generate APU (intermediate <bold>30</bold>) [<xref ref-type="bibr" rid="CR9">9</xref>]. During the early steps, the kinase PumH can recognize uridine, <bold>28</bold> or <bold>29</bold> as substrates and phosphorylation likely occurs at the C-2&#x02032; position, similarly to the recently-illustrated reaction by PolQ2 (the PumH homolog, a kinase in the biosynthesis of polyoxin) [<xref ref-type="bibr" rid="CR74">74</xref>]. Subsequently, the phosphate group is removed by PumD or by a housekeeping phosphatase. The compound <bold>30</bold> is then condensed to glutamine, a reaction catalyzed by the amide ligase PumK to yield the intermediate Gln-APU (<bold>31</bold>). After that, the intermediate <bold>31</bold> is <italic>N</italic>-hydroxylated by the oxidoreductase PumE to generate <bold>32</bold>. In a parallel way, another intermediate GAA is produced from glycine and arginine by the amidinotransferase PumN, and the GAA molecule is added to compound <bold>32</bold> by PumM leading to the final compound, PUM, which is transported out of the cell by PumL (transporter) [<xref ref-type="bibr" rid="CR71">71</xref>]. More recently, PumF has been identified as a positive regulator by controlling the transcription of the <italic>pumK&#x02013;N</italic> unit [<xref ref-type="bibr" rid="CR71">71</xref>].</p></sec></sec><sec id="Sec11"><title>Conclusions and perspectives</title><p id="Par54">Over the past decades, <italic>C</italic>-nucleoside antibiotics have distinguished themselves by diverse biological activities and unusual structural features, and they, as spotlight molecules, have attracted increasing research interests for pharmaceutical applications by medicinal chemists and pharmacologists. The present review mainly summarized the recent progress on the biosynthesis of <italic>C</italic>-nucleoside antibiotics, which may enlighten us to explore the future opportunities of these antibiotics for clinical applications. Furthermore, the technological innovations and conceptual breakthroughs have emerged with an accelerated rhythm, which would promise a renaissance in the future for the discovery of novel <italic>C</italic>-nucleoside antibiotics.</p><p id="Par55">With the considerable advances in genome sequencing technology, particularly in the past decade, enormous reservoirs of microbial genomes have become explosively available [<xref ref-type="bibr" rid="CR75">75</xref>]. Scientists have been enabled with the unprecedented power, for the first time, to create chemical diversities of more novel <italic>C</italic>-nucleoside antibiotics towards enhanced/improved properties. We could envision that more BGCs related to <italic>C</italic>-nucleoside antibiotics will be rapidly and rationally accessed by targeted genome mining with great assistance of big data and artificial intelligence (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). Moreover, molecular phylogeny of key biosynthetic genes present in their gene clusters can be used as a pre-screening method to prioritize gene clusters for detailed biosynthetic analysis and molecule expression studies from a large pool of sequenced or un-sequenced microorganisms [<xref ref-type="bibr" rid="CR76">76</xref>]. Besides, modifying the promoters, manipulating the regulatory genes, and activating the silent gene clusters by the CRISPR/Cas9 (derived) technologies, confer scientists with enormous opportunities for further targeted discovery of new <italic>C</italic>-nucleoside compounds [<xref ref-type="bibr" rid="CR77">77</xref>].<fig id="Fig8"><label>Fig. 8</label><caption><p>Strategies for rapidly and rationally accessing novel <italic>C</italic>-nucleoside antibiotics. As shown in this figure, three strategies, involving targeted genome mining, combinatorial biosynthesis, and in vitro reaction, were delineated for rapidly accessing chemical diversities of <italic>C</italic>-nucleoside antibiotics in the future</p></caption><graphic xlink:href="12934_2021_1722_Fig8_HTML" id="MO8"/></fig></p><p id="Par56">Furthermore, we do expect, with accessing more BGCs coding for <italic>C</italic>-nucleoside molecules, that scientists will be provided with great possibilities to generate <italic>C</italic>-nucleoside diversities by more extensive synthetic biology-based strategies, including precursor-directed biosynthesis, mutasynthesis, combinatorial biosynthesis, and other biosynthetic manipulations [<xref ref-type="bibr" rid="CR10">10</xref>]. Also, the actinobacteria chassis can be further engineered by feeding intermediates to the knockout mutant for increasing diversities of the final antibiotic products. Indeed, it would be of great expectation for scientists to develop an in vitro reaction platform for high-efficient generation of <italic>C</italic>-nucleoside analogs (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). We can anticipate, with more novel enzyme tools for <italic>C</italic>-nucleoside biosynthetic pathway illustrated and available, that opportunities to discover and generate improved <italic>C</italic>-nucleoside antibiotics in the future will be accelerated in a more rational and economical way [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par57">In the past, clinical application of the <italic>C</italic>-nucleoside antibiotics has been severely hampered accounting for their potential toxicities and limited diversities, nevertheless, <italic>C</italic>-nucleoside related drugs (such as Remdesivir) with potent clinical efficacies have been artificially created and approved to combat epidemic diseases [<xref ref-type="bibr" rid="CR79">79</xref>]. In this respect, more combined and intensive efforts should be paid in the future for targeted discovery of more <italic>C</italic>-nucleoside molecules from natural reservoir of microbial genomes under the guidance of multiple strategies.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>SDM</term><def><p id="Par2">Showdomycin</p></def></def-item><def-item><term>MIN</term><def><p id="Par3">Minimycin</p></def></def-item><def-item><term>FOR-A</term><def><p id="Par4">Formycin A</p></def></def-item><def-item><term>PRF-A</term><def><p id="Par5">Pyrazofurin A</p></def></def-item><def-item><term>MAL-A</term><def><p id="Par6">Malayamycin A</p></def></def-item><def-item><term>PUM</term><def><p id="Par7">Pseudouridimycin</p></def></def-item><def-item><term>&#x003a8;</term><def><p id="Par8">Pseudouridine</p></def></def-item><def-item><term>BGC</term><def><p id="Par9">Biosynthetic gene cluster</p></def></def-item><def-item><term>NRPS</term><def><p id="Par10">Non-ribosomal peptide synthetase</p></def></def-item><def-item><term>A</term><def><p id="Par11">Adenylation domain</p></def></def-item><def-item><term>Ox</term><def><p id="Par12">Oxidase domain</p></def></def-item><def-item><term>T</term><def><p id="Par13">Thiolation domain</p></def></def-item><def-item><term>TE</term><def><p id="Par14">Thioesterase domain</p></def></def-item><def-item><term>Tau</term><def><p id="Par15">Tautomerase domain</p></def></def-item><def-item><term>COF</term><def><p id="Par16">Coformycin</p></def></def-item><def-item><term>PRPP</term><def><p id="Par17">Phosphoribosyl pyrophosphate</p></def></def-item><def-item><term><sc>l</sc>-Lys</term><def><p id="Par18"><sc>l</sc>-lysine</p></def></def-item><def-item><term>DCOP</term><def><p id="Par19">3,5-Dicarboxy-4-oxo-4,5-dihydropyrazole</p></def></def-item><def-item><term>ADCP</term><def><p id="Par20">4-Amino-3,5-dicarboxypyrazole</p></def></def-item><def-item><term>HDCP</term><def><p id="Par21">4-Hydroxy-3,5-dicarboxypyrazole</p></def></def-item><def-item><term>&#x003b2;-RFAP</term><def><p id="Par22">&#x003b2;-Ribofuranosyl-aminobenzene 5&#x02032;-phosphate</p></def></def-item><def-item><term><italic>p</italic>ABA</term><def><p id="Par23"><italic>p</italic>-Aminobenzoate</p></def></def-item><def-item><term>SAICAR</term><def><p id="Par24">Phosphoribosylaminoimidazole-succinocarboxamide</p></def></def-item><def-item><term>RNAP</term><def><p id="Par25">RNA polymerase</p></def></def-item><def-item><term>NTP</term><def><p id="Par26">Nucleoside-triphosphate</p></def></def-item><def-item><term>bRNAP</term><def><p id="Par27">Bacterial RNAP polymerase</p></def></def-item><def-item><term>hRNAP</term><def><p id="Par28">Human RNA polymerase</p></def></def-item><def-item><term>PU</term><def><p id="Par29">Pseudouridine</p></def></def-item><def-item><term>APU</term><def><p id="Par30">5&#x02032;-Amino pseudouridine</p></def></def-item><def-item><term>Glu-APU</term><def><p id="Par31">Glutamine-APU</p></def></def-item><def-item><term>GAA</term><def><p id="Par32">Guanidinoacetic acid</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Meng Zhang, Liyuan Kong and Rong Gong contributed equally to this paper</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>MZ, LK, and RG wrote the manuscript. MI helped with preparation of the manuscript. WC conceived and wrote the manuscript. SD, ZD, MS revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Grants National Key R &#x00026; D Program of China (2018YFA0903203), the National Natural Science Foundation of China (31770041, 31970052, and 32170026), the Hubei Province&#x02019;s Outstanding Medical Academic Leader program, and the Open Funding Project of the State Key Laboratory of Microbial Metabolism (MMLKF19-03).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets supporting the review are included within the article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par58">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par59">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">The authors declare no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Wan</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Natural and engineered biosynthesis of nucleoside antibiotics in <italic>Actinomycetes</italic></article-title><source>J Ind Microbiol Biotechnol</source><year>2016</year><volume>43</volume><issue>2&#x02013;3</issue><fpage>401</fpage><lpage>417</lpage><?supplied-pmid 26153500?><pub-id pub-id-type="pmid">26153500</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>CT</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Chemical logic and enzymatic machinery for biological assembly of peptidyl nucleoside antibiotics</article-title><source>ACS Chem Biol</source><year>2011</year><volume>6</volume><issue>10</issue><fpage>1000</fpage><lpage>1007</lpage><?supplied-pmid 21851099?><pub-id pub-id-type="pmid">21851099</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stambask&#x000fd;</surname><given-names>J</given-names></name><name><surname>Hocek</surname><given-names>M</given-names></name><name><surname>Kocovsk&#x000fd;</surname><given-names>P</given-names></name></person-group><article-title><italic>C</italic>-nucleosides: synthetic strategies and biological applications</article-title><source>Chem Rev</source><year>2009</year><volume>109</volume><issue>12</issue><fpage>6729</fpage><lpage>6764</lpage><?supplied-pmid 19761208?><pub-id pub-id-type="pmid">19761208</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamma</surname><given-names>T</given-names></name><name><surname>Ferr&#x000e9;-D&#x02032;&#x02032;Amar&#x000e9;</surname><given-names>AR</given-names></name></person-group><article-title>Pseudouridine synthases</article-title><source>Chem Biol</source><year>2006</year><volume>13</volume><issue>11</issue><fpage>1125</fpage><lpage>1135</lpage><?supplied-pmid 17113994?><pub-id pub-id-type="pmid">17113994</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palmu</surname><given-names>K</given-names></name><name><surname>Rosenqvist</surname><given-names>P</given-names></name><name><surname>Thapa</surname><given-names>K</given-names></name><name><surname>Ilina</surname><given-names>Y</given-names></name><name><surname>Siitonen</surname><given-names>V</given-names></name><name><surname>Baral</surname><given-names>B</given-names></name><etal/></person-group><article-title>Discovery of the showdomycin gene cluster from <italic>Streptomyces showdoensis</italic> ATCC 15227 yields insight into the biosynthetic logic of <italic>C</italic>-nucleoside antibiotics</article-title><source>ACS Chem Biol</source><year>2017</year><volume>12</volume><issue>6</issue><fpage>1472</fpage><lpage>1477</lpage><?supplied-pmid 28418235?><pub-id pub-id-type="pmid">28418235</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>YS</given-names></name><etal/></person-group><article-title>Divergent biosynthesis of <italic>C</italic>-nucleoside minimycin and indigoidine in bacteria</article-title><source>iScience</source><year>2019</year><volume>22</volume><fpage>430</fpage><lpage>440</lpage><?supplied-pmid 31816530?><pub-id pub-id-type="pmid">31816530</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparative investigation into formycin A and pyrazofurin A biosynthesis reveals branch pathways for the construction of <italic>C</italic>-nucleoside scaffolds</article-title><source>Appl Environ Microbiol</source><year>2020</year><volume>86</volume><issue>2</issue><fpage>e01971</fpage><lpage>e2019</lpage><?supplied-pmid 31676476?><pub-id pub-id-type="pmid">31676476</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>SA</given-names></name><name><surname>Ko</surname><given-names>Y</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Ogasawara</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name></person-group><article-title>Identification of the <italic>C</italic>-glycoside synthases during biosynthesis of the pyrazole-<italic>C</italic>-nucleosides formycin and pyrazofurin</article-title><source>Angew Chem Int Ed</source><year>2019</year><volume>58</volume><issue>46</issue><fpage>16512</fpage><lpage>16516</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosio</surname><given-names>M</given-names></name><name><surname>Gaspari</surname><given-names>E</given-names></name><name><surname>Iorio</surname><given-names>M</given-names></name><name><surname>Pessina</surname><given-names>S</given-names></name><name><surname>Medema</surname><given-names>MH</given-names></name><name><surname>Bernasconi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Analysis of the pseudouridimycin biosynthetic pathway provides insights into the formation of C-nucleoside antibiotics</article-title><source>Cell Chem Biol</source><year>2018</year><volume>25</volume><issue>5</issue><fpage>540</fpage><lpage>549.e4</lpage><?supplied-pmid 29551347?><pub-id pub-id-type="pmid">29551347</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Samborskyy</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Leadlay</surname><given-names>PF</given-names></name></person-group><article-title><italic>C</italic>-nucleoside formation in the biosynthesis of the antifungal malayamycin A</article-title><source>Cell Chem Biol</source><year>2019</year><volume>26</volume><issue>4</issue><fpage>493</fpage><lpage>501</lpage><?supplied-pmid 30713097?><pub-id pub-id-type="pmid">30713097</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraishi</surname><given-names>T</given-names></name><name><surname>Kuzuyama</surname><given-names>T</given-names></name></person-group><article-title>Recent advances in the biosynthesis of nucleoside antibiotics</article-title><source>J Antibiot (Tokyo)</source><year>2019</year><volume>72</volume><issue>12</issue><fpage>913</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">31554958</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><article-title>Discovery of novel bioactive natural products driven by genome mining</article-title><source>Drug Discov Ther</source><year>2018</year><volume>12</volume><issue>6</issue><fpage>318</fpage><lpage>328</lpage><?supplied-pmid 30674766?><pub-id pub-id-type="pmid">30674766</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>Y</given-names></name><name><surname>Kan&#x0014f;</surname><given-names>H</given-names></name><name><surname>Tsukuda</surname><given-names>Y</given-names></name><name><surname>Koyama</surname><given-names>H</given-names></name></person-group><article-title>Structure of a new class of <italic>C</italic>-nucleoside antibiotic, showdomycin</article-title><source>Tetrahedron Lett</source><year>1967</year><volume>8</volume><issue>42</issue><fpage>4105</fpage><lpage>4109</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalvoda</surname><given-names>L</given-names></name><name><surname>Farkas</surname><given-names>J</given-names></name><name><surname>Sorm</surname><given-names>F</given-names></name></person-group><article-title>Synthesis of showdomycin</article-title><source>Tetrahedron Lett</source><year>1970</year><volume>11</volume><issue>26</issue><fpage>2297</fpage><lpage>2300</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>H</given-names></name><name><surname>Mayama</surname><given-names>M</given-names></name><name><surname>Komatsu</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Shimaoka</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><article-title>Showdomycin, a new antibiotic from a <italic>Streptomyces</italic> sp</article-title><source>J Antibiot (Tokyo)</source><year>1964</year><volume>17</volume><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">14194952</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy-Burman</surname><given-names>S</given-names></name><name><surname>Roy-Burman</surname><given-names>P</given-names></name><name><surname>Visser</surname><given-names>DW</given-names></name></person-group><article-title>Showdomycin, a new nucleoside antibiotic</article-title><source>Cancer Res</source><year>1968</year><volume>28</volume><issue>8</issue><fpage>1605</fpage><lpage>1610</lpage><?supplied-pmid 5691758?><pub-id pub-id-type="pmid">5691758</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elstner</surname><given-names>EF</given-names></name><name><surname>Suhadolnik</surname><given-names>RJ</given-names></name></person-group><article-title>Nucleoside antibiotics. Biosynthesis of the maleimide nucleoside antibiotic, showdomycin, by <italic>Streptomyces showdoensis</italic></article-title><source>Biochemistry</source><year>1971</year><volume>10</volume><issue>19</issue><fpage>3608</fpage><lpage>3614</lpage><?supplied-pmid 5146574?><pub-id pub-id-type="pmid">5146574</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elstner</surname><given-names>EF</given-names></name><name><surname>Suhadolnik</surname><given-names>RJ</given-names></name></person-group><article-title>Nucleoside antibiotics. Asymmetric incorporation of glutamic acid and acetate into the maleimide ring of showdomycin by <italic>Streptomyces showdoensis</italic></article-title><source>Biochemistry</source><year>1972</year><volume>11</volume><issue>14</issue><fpage>2578</fpage><lpage>2584</lpage><?supplied-pmid 5045517?><pub-id pub-id-type="pmid">5045517</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elstner</surname><given-names>EF</given-names></name><name><surname>Suhadolnik</surname><given-names>RJ</given-names></name><name><surname>Allerhand</surname><given-names>A</given-names></name></person-group><article-title>Effect of changes in the pool of acetate on the incorporation and distribution of <sup>13</sup>C- and <sup>14</sup>C-labeled acetate into showdomycin by <italic>Streptomyces showdoensis</italic></article-title><source>J Biol Chem</source><year>1973</year><volume>248</volume><issue>15</issue><fpage>5385</fpage><lpage>5388</lpage><?supplied-pmid 4768905?><pub-id pub-id-type="pmid">4768905</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>SA</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name></person-group><article-title>Identification of a pyrrole intermediate which undergoes <italic>C</italic>-glycosidation and autoxidation to yield the final product in showdomycin biosynthesis</article-title><source>Angew Chem Int Ed</source><year>2021</year><volume>60</volume><issue>31</issue><fpage>17148</fpage><lpage>17154</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusakabe</surname><given-names>Y</given-names></name><name><surname>Nagatsu</surname><given-names>J</given-names></name><name><surname>Shibuya</surname><given-names>M</given-names></name><name><surname>Kawaguchi</surname><given-names>O</given-names></name><name><surname>Hirose</surname><given-names>C</given-names></name></person-group><article-title>Minimycin, a new antibiotic</article-title><source>J Antibiot (Tokyo)</source><year>1972</year><volume>25</volume><issue>1</issue><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">5010645</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tymiak</surname><given-names>AA</given-names></name><name><surname>Culver</surname><given-names>CA</given-names></name><name><surname>Goodman</surname><given-names>JF</given-names></name><name><surname>Seiner</surname><given-names>VS</given-names></name><name><surname>Sykes</surname><given-names>RB</given-names></name></person-group><article-title>Oxazinomycin produced by a <italic>Pseudomonas</italic> species</article-title><source>J Antibiot (Tokyo)</source><year>1984</year><volume>37</volume><issue>4</issue><fpage>416</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">6725147</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bernardo</surname><given-names>S</given-names></name><name><surname>Weigele</surname><given-names>M</given-names></name></person-group><article-title>Synthesis of oxazinomycin (minimycin)</article-title><source>J Org Chem</source><year>1977</year><volume>42</volume><issue>1</issue><fpage>109</fpage><lpage>112</lpage><?supplied-pmid 830847?><pub-id pub-id-type="pmid">830847</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haneishi</surname><given-names>T</given-names></name><name><surname>Okazaki</surname><given-names>T</given-names></name><name><surname>Hata</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>C</given-names></name><name><surname>Nomura</surname><given-names>M</given-names></name></person-group><article-title>Oxazinomycin, a new carbon-linked nucleoside antibiotic</article-title><source>J Antibiot (Tokyo)</source><year>1971</year><volume>24</volume><issue>11</issue><fpage>797</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">5140526</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Kusakabe</surname><given-names>Y</given-names></name><name><surname>Esumi</surname><given-names>S</given-names></name></person-group><article-title>The structure of minimycin, a novel carbon-linked nucleoside antibiotic related to &#x003b2;-pseudouridine</article-title><source>J Antibiot (Tokyo)</source><year>1972</year><volume>25</volume><issue>3</issue><fpage>151</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">5034811</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prajapati</surname><given-names>RK</given-names></name><name><surname>Rosenqvist</surname><given-names>P</given-names></name><name><surname>Palmu</surname><given-names>K</given-names></name><name><surname>M&#x000e4;kinen</surname><given-names>JJ</given-names></name><name><surname>Malinen</surname><given-names>AM</given-names></name><name><surname>Virta</surname><given-names>P</given-names></name><etal/></person-group><article-title>Oxazinomycin arrests RNA polymerase at the polythymidine sequences</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>19</issue><fpage>10296</fpage><lpage>10312</lpage><?supplied-pmid 31495891?><pub-id pub-id-type="pmid">31495891</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isono</surname><given-names>K</given-names></name><name><surname>Suhadolnik</surname><given-names>RJ</given-names></name></person-group><article-title>Biosynthesis of the <italic>C</italic>-nucleoside, minimycin: asymmetric incorporation of glutamate and acetate into the oxazine ring</article-title><source>J Antibiot (Tokyo)</source><year>1977</year><volume>30</volume><issue>3</issue><fpage>272</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">863787</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isono</surname><given-names>K</given-names></name><name><surname>Suhadolnik</surname><given-names>RJ</given-names></name></person-group><article-title>The biosynthesis of the nucleoside antibiotics: minimycin formation by <italic>Streptomyces hygroscopicus</italic></article-title><source>Ann N Y Acad Sci</source><year>1975</year><volume>255</volume><fpage>390</fpage><lpage>401</lpage><?supplied-pmid 1059367?><pub-id pub-id-type="pmid">1059367</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gan</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Gin</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Investigation of indigoidine synthetase reveals a conserved active-site base residue of nonribosomal peptide synthetase oxidases</article-title><source>J Am Chem Soc</source><year>2020</year><volume>142</volume><issue>25</issue><fpage>10931</fpage><lpage>10935</lpage><?supplied-pmid 32510939?><pub-id pub-id-type="pmid">32510939</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Takita</surname><given-names>T</given-names></name><name><surname>Koyama</surname><given-names>G</given-names></name><name><surname>Tadeuchi</surname><given-names>T</given-names></name><name><surname>Umezawa</surname><given-names>H</given-names></name></person-group><article-title>A new antibiotic, formycin</article-title><source>J Antibiot (Tokyo)</source><year>1964</year><volume>17</volume><fpage>96</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">14171222</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>&#x0014c;take</surname><given-names>N</given-names></name><name><surname>Yonehara</surname><given-names>H</given-names></name><name><surname>Isono</surname><given-names>K</given-names></name><name><surname>Igarashi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Studies on a new antibiotic, laurusin</article-title><source>Agric Biol Chem</source><year>1965</year><volume>29</volume><issue>4</issue><fpage>375</fpage><lpage>376</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suhadolnik</surname><given-names>RJ</given-names></name><name><surname>Uematsu</surname><given-names>T</given-names></name></person-group><article-title>Biosynthesis of the pyrrolopyrimidine nucleoside antibiotic, toyocamycin. VII. Origin of the pyrrole carbons and the cyano carbon</article-title><source>J Biol Chem</source><year>1970</year><volume>245</volume><issue>17</issue><fpage>4365</fpage><lpage>4371</lpage><?supplied-pmid 5498424?><pub-id pub-id-type="pmid">5498424</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krugh</surname><given-names>TR</given-names></name></person-group><article-title>Tautomerism of the nucleoside antibiotic formycin, as studied by carbon-13 nuclear magnetic resonance</article-title><source>J Am Chem Soc</source><year>1973</year><volume>95</volume><issue>14</issue><fpage>4761</fpage><lpage>4762</lpage><?supplied-pmid 4730666?><pub-id pub-id-type="pmid">4730666</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prusiner</surname><given-names>P</given-names></name><name><surname>Brennan</surname><given-names>T</given-names></name><name><surname>Sundaralingam</surname><given-names>M</given-names></name></person-group><article-title>Crystal structure and molecular conformation of formycin monohydrates. Possible origin of the anomalous circular dichroic spectra in formycin mono- and polynucleotides</article-title><source>Biochemistry</source><year>1973</year><volume>12</volume><issue>6</issue><fpage>1196</fpage><lpage>1202</lpage><?supplied-pmid 4688865?><pub-id pub-id-type="pmid">4688865</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishizuka</surname><given-names>M</given-names></name><name><surname>Sawa</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Takayama</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name></person-group><article-title>Biological studies on formycin and formycin B</article-title><source>J Antibiot (Tokyo)</source><year>1968</year><volume>21</volume><issue>1</issue><fpage>5</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">5673295</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>T</given-names></name><name><surname>Iwanaga</surname><given-names>J</given-names></name><name><surname>Aoyagi</surname><given-names>T</given-names></name><name><surname>Umezawa</surname><given-names>H</given-names></name></person-group><article-title>Antiviral effect of formycin and formycin B</article-title><source>J Antibiot (Tokyo)</source><year>1966</year><volume>19</volume><issue>6</issue><fpage>286</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">6013241</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dapp</surname><given-names>MJ</given-names></name><name><surname>Bonnac</surname><given-names>L</given-names></name><name><surname>Patterson</surname><given-names>SE</given-names></name><name><surname>Mansky</surname><given-names>LM</given-names></name></person-group><article-title>Discovery of novel ribonucleoside analogs with activity against human immunodeficiency virus type 1</article-title><source>J Virol</source><year>2014</year><volume>88</volume><issue>1</issue><fpage>354</fpage><lpage>363</lpage><?supplied-pmid 24155391?><pub-id pub-id-type="pmid">24155391</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>JF</given-names></name><name><surname>Paterson</surname><given-names>ARP</given-names></name><name><surname>Caldwell</surname><given-names>IC</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name></person-group><article-title>Biochemical effects of formycin, an adenosine analog</article-title><source>Cancer Res</source><year>1967</year><volume>27</volume><issue>4</issue><fpage>715</fpage><lpage>719</lpage><?supplied-pmid 4290625?><pub-id pub-id-type="pmid">4290625</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunimoto</surname><given-names>T</given-names></name><name><surname>Sawa</surname><given-names>T</given-names></name><name><surname>Wakashiro</surname><given-names>T</given-names></name><name><surname>Hori</surname><given-names>M</given-names></name><name><surname>Umezawa</surname><given-names>H</given-names></name></person-group><article-title>Biosynthesis of the formycin family</article-title><source>J Antibiot (Tokyo)</source><year>1971</year><volume>24</volume><issue>4</issue><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">5572753</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochi</surname><given-names>K</given-names></name><name><surname>Iwamoto</surname><given-names>S</given-names></name><name><surname>Hayase</surname><given-names>E</given-names></name><name><surname>Yashima</surname><given-names>S</given-names></name><name><surname>Okami</surname><given-names>Y</given-names></name></person-group><article-title>Biosynthesis of formycin. Role of certain amino acids in formycin biosynthesis</article-title><source>J Antibiot (Tokyo)</source><year>1974</year><volume>27</volume><issue>12</issue><fpage>909</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">4468276</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochi</surname><given-names>K</given-names></name><name><surname>Yashima</surname><given-names>S</given-names></name><name><surname>Eguchi</surname><given-names>Y</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name></person-group><article-title>Biosynthesis of formycin. Incorporation and distribution of <sup>13</sup>C-, <sup>14</sup>C-, and <sup>15</sup>N-labeled compounds into formycin</article-title><source>J Biol Chem</source><year>1979</year><volume>254</volume><issue>18</issue><fpage>8819</fpage><lpage>8824</lpage><?supplied-pmid 479162?><pub-id pub-id-type="pmid">479162</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>SA</given-names></name><name><surname>Ogasawara</surname><given-names>Y</given-names></name><name><surname>Ruszczycky</surname><given-names>MW</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name></person-group><article-title>Identification and characterization of enzymes catalyzing pyrazolopyrimidine formation in the biosynthesis of formycin A</article-title><source>Org Lett</source><year>2017</year><volume>19</volume><issue>6</issue><fpage>1426</fpage><lpage>1429</lpage><?supplied-pmid 28233490?><pub-id pub-id-type="pmid">28233490</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SA</given-names></name><name><surname>Ko</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Ogasawara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of the formycin A biosynthetic gene cluster from <italic>Streptomyces kaniharaensis</italic> illustrates the interplay between biological pyrazolopyrimidine formation and <italic>de Novo</italic> purine biosynthesis</article-title><source>J Am Chem Soc</source><year>2019</year><volume>141</volume><issue>15</issue><fpage>6127</fpage><lpage>6131</lpage><?supplied-pmid 30942582?><pub-id pub-id-type="pmid">30942582</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>de Crecy-Lagard</surname><given-names>V</given-names></name><name><surname>Richards</surname><given-names>NGJ</given-names></name></person-group><article-title>Whole-genome sequence of <italic>Streptomyces kaniharaensis</italic> Shomura and Niida SF-557</article-title><source>Microbiol Resour Announc</source><year>2020</year><volume>9</volume><issue>14</issue><fpage>e01434</fpage><lpage>e1519</lpage><?supplied-pmid 32241862?><pub-id pub-id-type="pmid">32241862</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Koyama</surname><given-names>G</given-names></name><name><surname>Iitaka</surname><given-names>Y</given-names></name><name><surname>Ohno</surname><given-names>M</given-names></name><name><surname>Yagisawa</surname><given-names>N</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structure of coformycin, an unusual nucleoside of microbial origin</article-title><source>J Am Chem Soc</source><year>1974</year><volume>96</volume><issue>13</issue><fpage>4327</fpage><lpage>4328</lpage><?supplied-pmid 4854435?><pub-id pub-id-type="pmid">4854435</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>K</given-names></name><name><surname>Tomita</surname><given-names>T</given-names></name><name><surname>Shin-Ya</surname><given-names>K</given-names></name><name><surname>Wakimoto</surname><given-names>T</given-names></name><name><surname>Kuzuyama</surname><given-names>T</given-names></name><name><surname>Nishiyama</surname><given-names>M</given-names></name></person-group><article-title>Discovery of unprecedented hydrazine-forming machinery in bacteria</article-title><source>J Am Chem Soc</source><year>2018</year><volume>140</volume><issue>29</issue><fpage>9083</fpage><lpage>9086</lpage><?supplied-pmid 30001119?><pub-id pub-id-type="pmid">30001119</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>de Crecy-Lagard</surname><given-names>V</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Richards</surname><given-names>NGJ</given-names></name><name><surname>Naismith</surname><given-names>JH</given-names></name></person-group><article-title>PMP-diketopiperazine adducts form at the active site of a PLP dependent enzyme involved in formycin biosynthesis</article-title><source>ChemComm</source><year>2019</year><volume>55</volume><issue>96</issue><fpage>14502</fpage><lpage>14505</lpage></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Radadiya</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>de Cr&#x000e9;cy-Lagard</surname><given-names>V</given-names></name><etal/></person-group><article-title>Uncovering the chemistry of C-C bond formation in <italic>C</italic>-nucleoside biosynthesis: crystal structure of a <italic>C</italic>-glycoside synthase/PRPP complex</article-title><source>ChemComm</source><year>2020</year><volume>56</volume><issue>55</issue><fpage>7617</fpage><lpage>7620</lpage></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerzon</surname><given-names>K</given-names></name><name><surname>DeLong</surname><given-names>DC</given-names></name><name><surname>Cline</surname><given-names>JC</given-names></name></person-group><article-title><italic>C</italic>-nucleosides: aspects of chemistry and mode of action</article-title><source>Pure Appl Chem</source><year>1971</year><volume>28</volume><issue>4</issue><fpage>489</fpage><lpage>497</lpage><?supplied-pmid 4947321?><pub-id pub-id-type="pmid">4947321</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>G</given-names></name><name><surname>Maeda</surname><given-names>K</given-names></name><name><surname>Umezawa</surname><given-names>H</given-names></name><name><surname>Iitaka</surname><given-names>Y</given-names></name></person-group><article-title>The structural studies of formycin and formycin B</article-title><source>Tetrahedron Lett</source><year>1966</year><volume>7</volume><issue>6</issue><fpage>597</fpage><lpage>602</lpage></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouton</surname><given-names>J</given-names></name><name><surname>Van Calenbergh</surname><given-names>S</given-names></name><name><surname>Hullaert</surname><given-names>J</given-names></name></person-group><article-title>Sydnone ribosides as a platform for the synthesis of pyrazole <italic>C</italic>-nucleosides: a unified synthesis of formycin B and pyrazofurin</article-title><source>Org Lett</source><year>2020</year><volume>22</volume><issue>23</issue><fpage>9287</fpage><lpage>9291</lpage><?supplied-pmid 33210930?><pub-id pub-id-type="pmid">33210930</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutowski</surname><given-names>GE</given-names></name><name><surname>Sweeney</surname><given-names>MJ</given-names></name><name><surname>DeLong</surname><given-names>DC</given-names></name><name><surname>Hamill</surname><given-names>RL</given-names></name><name><surname>Gerzon</surname><given-names>K</given-names></name><name><surname>Dyke</surname><given-names>RW</given-names></name></person-group><article-title>Biochemistry and biological effects of the pyrazofurins (pyrazomycins): initial clinical trial</article-title><source>Ann N Y Acad Sci</source><year>1975</year><volume>255</volume><fpage>544</fpage><lpage>551</lpage><?supplied-pmid 1059372?><pub-id pub-id-type="pmid">1059372</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>DH</given-names></name><name><surname>Sweeney</surname><given-names>MJ</given-names></name></person-group><article-title>Orotate phosphoribosyl transferase and orotidylic acid decarboxylase activities in liver and Morris hepatomas</article-title><source>Cancer Res</source><year>1973</year><volume>33</volume><issue>5</issue><fpage>1109</fpage><lpage>1112</lpage><?supplied-pmid 4349934?><pub-id pub-id-type="pmid">4349934</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadman</surname><given-names>EC</given-names></name><name><surname>Dix</surname><given-names>DE</given-names></name><name><surname>Handschumacher</surname><given-names>RE</given-names></name></person-group><article-title>Clinical, biological, and biochemical effects of pyrazofurin</article-title><source>Cancer Res</source><year>1978</year><volume>38</volume><issue>3</issue><fpage>682</fpage><lpage>688</lpage><?supplied-pmid 272228?><pub-id pub-id-type="pmid">272228</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olah</surname><given-names>E</given-names></name><name><surname>Lui</surname><given-names>MS</given-names></name><name><surname>Tzeng</surname><given-names>DY</given-names></name><name><surname>Weber</surname><given-names>G</given-names></name></person-group><article-title>Phase and cell cycle specificity of pyrazofurin action</article-title><source>Cancer Res</source><year>1980</year><volume>40</volume><issue>8 Pt 1</issue><fpage>2869</fpage><lpage>2875</lpage><?supplied-pmid 7388837?><pub-id pub-id-type="pmid">7388837</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worzalla</surname><given-names>JF</given-names></name><name><surname>Sweeney</surname><given-names>MJ</given-names></name></person-group><article-title>Pyrazofurin inhibition of purine biosynthesis via 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5&#x02032;-monophosphate formyltransferase</article-title><source>Cancer Res</source><year>1980</year><volume>40</volume><issue>5</issue><fpage>1482</fpage><lpage>1485</lpage><?supplied-pmid 7370986?><pub-id pub-id-type="pmid">7370986</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>PA</given-names></name><name><surname>Bodey</surname><given-names>GP</given-names></name><name><surname>Burgess</surname><given-names>MA</given-names></name><name><surname>Murphy</surname><given-names>WK</given-names></name><name><surname>Freireich</surname><given-names>EJ</given-names></name></person-group><article-title>A phase I study of pyrazofurin</article-title><source>Cancer</source><year>1977</year><volume>40</volume><issue>6</issue><fpage>2806</fpage><lpage>2809</lpage><?supplied-pmid 589556?><pub-id pub-id-type="pmid">589556</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Walker</surname><given-names>RT</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name><name><surname>Eckstein</surname><given-names>F</given-names></name></person-group><article-title>The clinical uses of nucleoside analogues in malignant disease</article-title><source>Nucleoside analogues: chemistry, biology, and medical applications</source><year>1979</year><publisher-loc>Boston</publisher-loc><publisher-name>Springer, US</publisher-name><fpage>409</fpage><lpage>436</lpage></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Morgenstern</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>G</given-names></name><name><surname>Chandra</surname><given-names>P</given-names></name><name><surname>Rabenau</surname><given-names>H</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus</article-title><source>Lancet</source><year>2003</year><volume>361</volume><issue>9374</issue><fpage>2045</fpage><lpage>2046</lpage><?supplied-pmid 7112442?><pub-id pub-id-type="pmid">12814717</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>JG</given-names></name><name><surname>Hamblin</surname><given-names>MR</given-names></name><name><surname>Sood</surname><given-names>GR</given-names></name><name><surname>Wightman</surname><given-names>RH</given-names></name></person-group><article-title>The biosynthesis of pyrazofurin and formycin</article-title><source>J Chem Soc Chem Commun</source><year>1980</year><volume>19</volume><fpage>917</fpage><lpage>918</lpage></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Rothchild</surname><given-names>KW</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><etal/></person-group><article-title>The biosynthetic gene cluster of pyrazomycin-A <italic>C</italic>-nucleoside antibiotic with a rare pyrazole moiety</article-title><source>ChemBioChem</source><year>2020</year><volume>21</volume><issue>5</issue><fpage>644</fpage><lpage>649</lpage><?supplied-pmid 31482654?><pub-id pub-id-type="pmid">31482654</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Benner JP, Boehlendorf BGH, Kipps MR, et al. Biocidal compounds and their preparation. WIPO, WO2003GB00063. 2003.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanessian</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Chenel</surname><given-names>C</given-names></name><name><surname>Machaalani</surname><given-names>R</given-names></name><name><surname>Loiseleur</surname><given-names>O</given-names></name></person-group><article-title>Total synthesis of <italic>N</italic>-malayamycin A and related bicyclic purine and pyrimidine nucleosides</article-title><source>J Org Chem</source><year>2005</year><volume>70</volume><issue>17</issue><fpage>6721</fpage><lpage>6734</lpage><?supplied-pmid 16095292?><pub-id pub-id-type="pmid">16095292</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Csukai</surname><given-names>M</given-names></name><name><surname>Corran</surname><given-names>A</given-names></name><name><surname>Crowley</surname><given-names>P</given-names></name><name><surname>Solomon</surname><given-names>PS</given-names></name><name><surname>Oliver</surname><given-names>RP</given-names></name></person-group><article-title>Malayamycin, a new streptomycete antifungal compound, specifically inhibits sporulation of <italic>Stagonospora nodorum</italic> (Berk) Castell and Germano, the cause of wheat glume blotch disease</article-title><source>Pest Manag Sci</source><year>2008</year><volume>64</volume><issue>12</issue><fpage>1294</fpage><lpage>1302</lpage><?supplied-pmid 18683907?><pub-id pub-id-type="pmid">18683907</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Malley</surname><given-names>PA</given-names></name></person-group><article-title>Pseudouridimycin: light in the darkness of antimicrobial resistance</article-title><source>Clin Nurse Spec</source><year>2018</year><volume>32</volume><issue>3</issue><fpage>114</fpage><lpage>115</lpage><?supplied-pmid 29621104?><pub-id pub-id-type="pmid">29621104</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffioli</surname><given-names>SI</given-names></name><name><surname>Sosio</surname><given-names>M</given-names></name><name><surname>Ebright</surname><given-names>RH</given-names></name><name><surname>Donadio</surname><given-names>S</given-names></name></person-group><article-title>Discovery, properties, and biosynthesis of pseudouridimycin, an antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase</article-title><source>J Ind Microbiol Biotechnol</source><year>2019</year><volume>46</volume><issue>3&#x02013;4</issue><fpage>335</fpage><lpage>343</lpage><?supplied-pmid 30465105?><pub-id pub-id-type="pmid">30465105</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chellat</surname><given-names>MF</given-names></name><name><surname>Riedl</surname><given-names>R</given-names></name></person-group><article-title>Pseudouridimycin: the first nucleoside analogue that selectively inhibits bacterial RNA polymerase</article-title><source>Angew Chem Int Ed</source><year>2017</year><volume>56</volume><issue>43</issue><fpage>13184</fpage><lpage>13186</lpage></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffioli</surname><given-names>SI</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Degen</surname><given-names>D</given-names></name><name><surname>Carzaniga</surname><given-names>T</given-names></name><name><surname>Del Gatto</surname><given-names>G</given-names></name><name><surname>Serina</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase</article-title><source>Cell</source><year>2017</year><volume>169</volume><issue>7</issue><fpage>1240</fpage><lpage>1248.e23</lpage><?supplied-pmid 28622509?><pub-id pub-id-type="pmid">28622509</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabbad</surname><given-names>AH</given-names></name><name><surname>Agoni</surname><given-names>C</given-names></name><name><surname>Olotu</surname><given-names>FA</given-names></name><name><surname>Soliman</surname><given-names>ME</given-names></name></person-group><article-title>Microbes, not humans: exploring the molecular basis of pseudouridimycin selectivity towards bacterial and not human RNA polymerase</article-title><source>Biotechnol Lett</source><year>2019</year><volume>41</volume><issue>1</issue><fpage>115</fpage><lpage>128</lpage><?supplied-pmid 30377869?><pub-id pub-id-type="pmid">30377869</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabbad</surname><given-names>AH</given-names></name><name><surname>Olotu</surname><given-names>FA</given-names></name><name><surname>Soliman</surname><given-names>ME</given-names></name></person-group><article-title>Computer-aided structural and molecular insights into the mechanisms by which pseudouridimycin (PUM) disrupts cleft extension in bacterial RNA polymerase to block DNA entry and exit</article-title><source>Lett Drug Des Discov</source><year>2021</year><volume>18</volume><issue>6</issue><fpage>542</fpage><lpage>550</lpage></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname><given-names>M</given-names></name><name><surname>Davatgarbenam</surname><given-names>S</given-names></name><name><surname>Serina</surname><given-names>S</given-names></name><name><surname>Criscenzo</surname><given-names>P</given-names></name><name><surname>Zdouc</surname><given-names>MM</given-names></name><name><surname>Simone</surname><given-names>M</given-names></name><etal/></person-group><article-title>Blocks in the pseudouridimycin pathway unlock hidden metabolites in the <italic>Streptomyces</italic> producer strain</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>5827</fpage><?supplied-pmid 33712632?><pub-id pub-id-type="pmid">33712632</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohringer</surname><given-names>N</given-names></name><name><surname>Patras</surname><given-names>MA</given-names></name><name><surname>Schaberle</surname><given-names>TF</given-names></name></person-group><article-title>Heterologous expression of pseudouridimycin and description of the corresponding minimal biosynthetic gene cluster</article-title><source>Molecules</source><year>2021</year><volume>26</volume><issue>2</issue><fpage>510</fpage><?supplied-pmid 33478059?><pub-id pub-id-type="pmid">33478059</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenqvist</surname><given-names>P</given-names></name><name><surname>Palmu</surname><given-names>K</given-names></name><name><surname>Prajapati</surname><given-names>RK</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Niemi</surname><given-names>J</given-names></name><name><surname>Belogurov</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Characterization of <italic>C</italic>-nucleoside antimicrobials from <italic>Streptomyces albus</italic> DSM 40763: strepturidin is pseudouridimycin</article-title><source>Cancer Res</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>8935</fpage></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draelos</surname><given-names>MM</given-names></name><name><surname>Thanapipatsiri</surname><given-names>A</given-names></name><name><surname>Sucipto</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name></person-group><article-title>Cryptic phosphorylation in nucleoside natural product biosynthesis</article-title><source>Nat Chem Biol</source><year>2020</year><volume>17</volume><issue>2</issue><fpage>213</fpage><lpage>221</lpage><?supplied-pmid 33257873?><pub-id pub-id-type="pmid">33257873</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z-J</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Huo</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>Y-J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genome mining and biosynthesis of primary amine-acylated desferrioxamines in a marine gliding bacterium</article-title><source>Org Lett</source><year>2020</year><volume>22</volume><issue>3</issue><fpage>939</fpage><lpage>943</lpage><?supplied-pmid 31994894?><pub-id pub-id-type="pmid">31994894</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>H-S</given-names></name></person-group><article-title>Phylogeny-guided (meta)genome mining approach for the targeted discovery of new microbial natural products</article-title><source>J Ind Microbiol Biotechnol</source><year>2017</year><volume>44</volume><issue>2</issue><fpage>285</fpage><lpage>293</lpage><?supplied-pmid 27885438?><pub-id pub-id-type="pmid">27885438</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MM</given-names></name><name><surname>Wong</surname><given-names>FT</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>YH</given-names></name><name><surname>Heng</surname><given-names>E</given-names></name><etal/></person-group><article-title>CRISPR&#x02013;Cas9 strategy for activation of silent <italic>Streptomyces</italic> biosynthetic gene clusters</article-title><source>Nat Chem Biol</source><year>2017</year><volume>13</volume><issue>6</issue><fpage>607</fpage><lpage>609</lpage></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeiffer</surname><given-names>M</given-names></name><name><surname>Nidetzky</surname><given-names>B</given-names></name></person-group><article-title>Reverse <italic>C</italic>-glycosidase reaction provides <italic>C</italic>-nucleotide building blocks of xenobiotic nucleic acids</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>6270</fpage><?supplied-pmid 33293530?><pub-id pub-id-type="pmid">33293530</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leegwater</surname><given-names>E</given-names></name><name><surname>Strik</surname><given-names>A</given-names></name><name><surname>Wilms</surname><given-names>EB</given-names></name><name><surname>Bosma</surname><given-names>LBE</given-names></name><name><surname>Burger</surname><given-names>DM</given-names></name><name><surname>Ottens</surname><given-names>TH</given-names></name><etal/></person-group><article-title>Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with <italic>P</italic>-glycoprotein inhibitors</article-title><source>Clin Infect Dis</source><year>2020</year><volume>72</volume><issue>7</issue><fpage>1256</fpage><lpage>1258</lpage></element-citation></ref></ref-list></back></article>